InMode Ltd. (NASDAQ:INMD) Q4 2022 Results Conference Call February 14, 2023 8:30 AM ET
Company Participants
Miri Segal - Investor Relations, MS-IR LLC
Moshe Mizrahy - Chairman and Chief Executive Officer
Dr. Michael Kreindel - Co-Founder and Chief Technology Officer
Yair Malca - Chief Financial Officer
Shakil Lakhani - President, North America
Dr. Spero Theodorou - Chief Medical Officer
Rafael Lickerman - VP of Finance
Conference Call Participants
Matt Miksic - Barclays
Jon Lee - Jefferies
Kyle Rose - Canaccord Genuity
Mike Matson - Needham & Company
Jeff Johnson - Baird
Operator
Good morning, and welcome to InMode Fourth Quarter and Full Year Financial Results Conference Call. All participants will be in a listen-only mode. [Operator instructions] Please note this event is being recorded.
I'd now like to turn the conference over to Miri Segal, MS IR. Please go ahead.
Miri Segal
Thank you, operator and everyone, for joining us today. Welcome to our conference call.
Before we begin, I would like to remind our listeners that certain information provided on this call may contain forward-looking statements, and that the safe harbor statement outlined in today's earnings release also pertains to this call. If you have not received a copy of the release, please go to the Investor Relations section of the Company's website.
Changes in business, competitive, technological, regulatory and other factors could cause actual results to differ materially from those expressed by the forward-looking statements made today. Our historical results are not necessarily indicative of future performance. As such, we can give no assurance as to the accuracy of our forward-looking statements and assume no obligation to update them, except as required by law.
With that, I'd like to pass the call over to Moshe Mizrahy, Chairman and CEO. Moshe, please go ahead.
Moshe Mizrahy
Thank you, Miri, and to everybody who joining us. With me today are Dr. Michael Kreindel, our Co-Founder and Chief Technology Officer; Yair Malca, our Chief Financial Officer; Shakil Lakhani, our President in North America; Dr. Spero Theodorou, our Chief Medical Officer; and Rafael Likaman, our VP of Finance. Following our prepared remarks, we will all be available to answer your questions.
We are pleased to report another record quarter with Q4 revenue of $133.6 million and $454.3 million for the full year, an increase of 21% as compared to Q4 of 2021, and an increase of 27% compared to the full year 2021. This is a record level of revenue for an aesthetic medical company, and was especially remarkable and exciting since we are achieving this milestone during challenging global time.